Cargando…

Effects of novel HDAC inhibitors on urothelial carcinoma cells

BACKGROUND: Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear, however, whether inhibition of all 11 zinc-dependent HDACs or of individual enzymes is more efficacious and specific. Here, we investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaletsch, Aline, Pinkerneil, Maria, Hoffmann, Michèle J., Jaguva Vasudevan, Ananda A., Wang, Chenyin, Hansen, Finn K., Wiek, Constanze, Hanenberg, Helmut, Gertzen, Christoph, Gohlke, Holger, Kassack, Matthias U., Kurz, Thomas, Schulz, Wolfgang A., Niegisch, Günter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069857/ https://www.ncbi.nlm.nih.gov/pubmed/30064501 http://dx.doi.org/10.1186/s13148-018-0531-y

Ejemplares similares

HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2019)

Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2022)

Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
por: Hölscher, Alexander S., et al.
Publicado: (2018)

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
por: Pinkerneil, Maria, et al.
Publicado: (2016)

Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1
por: Wang, Chenyin, et al.
Publicado: (2020)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells
por: Schrenk, Christian, et al.
Publicado: (2023)

The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors
por: Hoffmann, Michèle J., et al.
Publicado: (2016)

Foamy Viruses, Bet, and APOBEC3 Restriction
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2021)

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
por: Grunewald, Camilla M., et al.
Publicado: (2021)

APOBEC3B Activity Is Prevalent in Urothelial Carcinoma Cells and Only Slightly Affected by LINE-1 Expression
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2018)

Understanding BRCA2 Function as a Tumor Suppressor Based on Domain-Specific Activities in DNA Damage Responses
por: Andreassen, Paul R., et al.
Publicado: (2021)

Canonical Notch signalling is inactive in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
por: Lehmann, Maria, et al.
Publicado: (2014)

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma
por: Droop, Johanna, et al.
Publicado: (2017)

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019)

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
por: Hoffmann, Michèle J., et al.
Publicado: (2021)

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
por: Rodrigues Moita, Ana J., et al.
Publicado: (2020)

HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma
por: Kreimer, Ulrike, et al.
Publicado: (2013)

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021)

Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells
por: Koutsogiannouli, Evangelia A., et al.
Publicado: (2017)

HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for “Off-the-Shelf” Immunotherapy
por: Hoerster, Keven, et al.
Publicado: (2021)

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells
por: Höhn, Annika, et al.
Publicado: (2016)

Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer
por: Knievel, Judith, et al.
Publicado: (2014)

Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

Contingencies of UTX/KDM6A Action in Urothelial Carcinoma
por: Lang, Alexander, et al.
Publicado: (2019)

The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells
por: Heubach, Judith, et al.
Publicado: (2015)

Spotlight on CYP4B1
por: Röder, Annika, et al.
Publicado: (2023)

The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines
por: Bollmann, Lukas M., et al.
Publicado: (2022)

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2018)

Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines
por: Lang, Alexander, et al.
Publicado: (2020)

Oxa Analogues of Nexturastat A Demonstrate Improved HDAC6 Selectivity and Superior Antileukaemia Activity
por: Pflieger, Marc, et al.
Publicado: (2021)

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
por: Sinatra, Laura, et al.
Publicado: (2020)

Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2017)

A Novel MCPH1 Isoform Complements the Defective Chromosome Condensation of Human MCPH1-Deficient Cells
por: Gavvovidis, Ioannis, et al.
Publicado: (2012)

Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines
por: Skowron, Margaretha A., et al.
Publicado: (2019)

A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR T cells
por: Bister, Arthur, et al.
Publicado: (2021)

Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines
por: Skowron, Margaretha A., et al.
Publicado: (2015)

Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines
por: Bandolik, Jan J., et al.
Publicado: (2019)

A functional conserved intronic G run in HIV-1 intron 3 is critical to counteract APOBEC3G-mediated host restriction
por: Widera, Marek, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_uked2utg82h4keatu8rs2ujeir